Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VTYX - Ventyx Biosciences, Inc.
Market Cap 2.15B P/E - EPS this Y 34.50% Ern Qtrly Grth -
Income -171.3M Forward P/E -11.46 EPS next Y -2.80% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 5.76 EPS next 5Y - 52W High Chg -22.00%
Recommedations 2.10 Quick Ratio 13.25 Shares Outstanding 70.67M 52W Low Chg 143.00%
Insider Own 3.31% ROA -35.29% Shares Float 49.68M Beta 0.37
Inst Own 91.55% ROE -56.29% Shares Shorted/Prior 8.60M/9.34M Price 36.68
Gross Margin - Profit Margin - Avg. Volume 725,169 Target Price 10.00
Oper. Margin - Earnings Date Nov 4 Volume 316,151 Change -1.37%
Healthcare | Biotechnology | United States
About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Ventyx Biosciences, Inc. News
12/14/24 Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
11/17/24 Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
11/12/24 Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
11/12/24 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
11/07/24 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
10/29/24 These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
10/15/24 Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
09/24/24 VTYX Stock Rises on Strategic Equity Investment Deal With SNY
09/23/24 Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
09/23/24 Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
09/06/24 Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
08/30/24 Ventyx Biosciences Announces Departure of Chief Financial Officer
08/30/24 Novo builds heart failure case for semaglutide; Ventyx CFO departs
08/28/24 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
08/08/24 Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
07/30/24 Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat
07/29/24 Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
07/29/24 Ventyx’s TYK2 drug suffers second setback
07/06/24 Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
06/05/24 Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Nuss John Chief Scientific Off.. Chief Scientific Officer Dec 20 Sell 2.1179 17,628 37,334 262,118 12/21/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Dec 20 Sell 2.1179 5,293 11,210 282,119 12/21/23
Mohan Raju CEO and President CEO and President Dec 20 Sell 2.1179 58,860 124,660 1,570,719 12/21/23
Mohan Raju CEO and President CEO and President Dec 17 Option 0.00 116,668 1,629,579 12/19/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Dec 17 Option 0.00 34,931 279,746 12/19/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Dec 17 Option 0.00 10,479 287,412 12/19/23
NSV Partners III LP 10% Owner 10% Owner Oct 09 Sell 30.0264 49,152 1,475,858 8,439,635 10/11/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Oct 05 Sell 29.11 30,000 873,300 1,512,911 10/06/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Oct 05 Option 8.04 30,000 241,200 1,542,911 10/06/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Oct 03 Sell 30.31 15,000 454,650 276,548 10/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Oct 03 Option 8.04 15,000 120,600 291,548 10/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Oct 03 Option 3.93 10,000 39,300 254,815 10/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Oct 03 Sell 30.33 10,000 303,300 244,815 10/04/23
Subramaniam Somu Director Director Sep 18 Sell 37.8123 56,665 2,142,634 8,488,787 09/20/23
NSV Partners III LP 10% Owner 10% Owner Sep 18 Sell 37.8123 56,665 2,142,634 8,488,787 09/20/23
Sandborn William J. See Remarks See Remarks Aug 31 Sell 33.64 11,900 400,316 48,389 09/01/23
Sandborn William J. See Remarks See Remarks Aug 31 Option 14.85 11,900 176,715 60,289 09/01/23
Sandborn William J. See Remarks See Remarks Aug 08 Sell 32.9 3,494 114,953 24,194 08/08/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Aug 07 Sell 34.1 30,000 1,023,000 1,512,911 08/08/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Aug 07 Option 8.04 30,000 241,200 1,542,911 08/08/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Aug 03 Sell 35.74 10,000 357,400 244,815 08/04/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Aug 03 Option 0.2 10,000 2,000 254,815 08/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Aug 03 Sell 35.73 15,000 535,950 276,548 08/04/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Aug 03 Option 8.04 15,000 120,600 291,548 08/04/23
Subramaniam Somu Director Director Jul 28 Sell 37.56 11,414 428,710 8,545,452 08/01/23
NSV Partners III LP 10% Owner 10% Owner Jul 28 Sell 37.56 11,414 428,710 8,545,452 08/01/23
Auster Martin Chief Financial Offi.. Chief Financial Officer Jul 25 Sell 35.54 28,000 995,120 47,649 07/26/23
Auster Martin Chief Financial Offi.. Chief Financial Officer Jul 25 Option 3.45 28,000 96,600 75,649 07/26/23
NSV Partners III LP Director Director Jul 07 Sell 35.91 100,000 3,591,000 9,552,965 07/19/23
Subramaniam Somu Director Director Jul 07 Sell 35.91 100,000 3,591,000 9,552,965 07/19/23
NSV Partners III LP Director Director Jul 11 Sell 37.58 31,921 1,199,591 8,556,866 07/13/23
Subramaniam Somu Director Director Jul 11 Sell 37.58 31,921 1,199,591 8,556,866 07/13/23
NSV Partners III LP 10% Owner 10% Owner Jul 03 Sell 37.74 134,080 5,060,179 9,652,965 07/06/23
Subramaniam Somu Director Director Jul 03 Sell 37.74 134,080 5,060,179 9,652,965 07/06/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Jul 05 Sell 39.14 30,000 1,174,200 1,512,911 07/05/23
Mohan Raju Chief Executive Offi.. Chief Executive Officer Jul 05 Option 8.04 29,785 239,471 1,542,911 07/05/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jul 03 Sell 36.86 20,000 737,200 244,815 07/05/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jul 03 Option 0.2 20,000 4,000 264,815 07/05/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Jul 03 Sell 36.75 15,000 551,250 276,548 07/05/23
Krueger Christopher W Chief Business Offic.. Chief Business Officer Jul 03 Option 4.12 15,000 61,800 291,548 07/05/23
Sandborn William J. See Remarks See Remarks Jul 03 Sell 40 15,387 615,480 27,688 07/05/23
Sandborn William J. See Remarks See Remarks Jul 03 Option 14.85 11,900 176,715 60,289 07/05/23
Sandborn William J. See Remarks See Remarks Jun 23 Sell 32.47 10,790 350,351 48,389 06/27/23
Sandborn William J. See Remarks See Remarks Jun 23 Option 0.2 10,790 2,158 59,179 06/27/23
Sandborn William J. See Remarks See Remarks Jun 15 Sell 34.31 3,487 119,639 31,175 06/16/23
Subramaniam Somu Director Director Jun 14 Sell 35.0757 50,000 1,753,785 9,787,045 06/16/23
NSV Partners III LP 10% Owner 10% Owner Jun 14 Sell 35.0757 50,000 1,753,785 9,787,045 06/16/23
Subramaniam Somu Director Director Jun 06 Sell 35.53 40,000 1,421,200 9,837,045 06/08/23
NSV Partners III LP 10% Owner 10% Owner Jun 06 Sell 35.53 40,000 1,421,200 9,837,045 06/08/23
Nuss John Chief Scientific Off.. Chief Scientific Officer Jun 05 Sell 34.46 10,000 344,600 244,815 06/07/23